Regional variation in the potentially inappropriate first-line use of fluoroquinolones in Canada as a key to antibiotic stewardship? A drug utilization review study

Simple item page
dc.contributor.authorSt-Jean, Audray
dc.contributor.authorChateau, Dan
dc.contributor.authorDahl, Matthew
dc.contributor.authorErnst, Pierre
dc.contributor.authorDaneman, Nick
dc.contributor.authorSketris, Ingrid S.
dc.contributor.authorZhang, Jianguo
dc.contributor.authorMarra, Fawziah
dc.contributor.authorQuail, Jacqueline
dc.contributor.authorBugden, Shawn
dc.date.accessioned2021-08-08T00:03:28Z
dc.date.available2021-08-08T00:03:28Z
dc.date.issued2021-08-03
dc.date.updated2021-08-08T00:03:27Z
dc.description.abstractAbstract Background Serious adverse effects of fluoroquinolone antibiotics have been described for more than decade. Recently, several drug regulatory agencies have advised restricting their use in milder infections for which other treatments are available, given the potential for disabling and possibly persistent side effects. We aimed to describe variations in fluoroquinolone use for initial treatment of urinary tract infection (UTI), acute bacterial sinusitis (ABS), and acute exacerbation of chronic obstructive pulmonary disease (AECOPD) in the outpatient setting across Canada. Methods Using administrative health data from six provinces, we identified ambulatory visits with a diagnosis of uncomplicated UTI, uncomplicated AECOPD or ABS. Antibiotic exposure was determined by the first antibiotic dispensed within 5 days of the visit. Results We identified 4,303,144 uncomplicated UTI events among 2,170,027 women; the proportion of events treated with fluoroquinolones, mostly ciprofloxacin, varied across provinces, ranging from 18.6% (Saskatchewan) to 51.6% (Alberta). Among 3,467,678 ABS events (2,087,934 patients), between 2.2% (Nova Scotia) and 11.2% (Ontario) were dispensed a fluoroquinolone. For 1,319,128 AECOPD events among 598,347 patients, fluoroquinolones, mostly levofloxacin and moxifloxacin, ranged from 5.8% (Nova Scotia) to 35.6% (Ontario). The proportion of uncomplicated UTI and ABS events treated with fluoroquinolones declined over time, whereas it remained relatively stable for AECOPD. Conclusions Fluoroquinolones were commonly used as first-line therapies for uncomplicated UTI and AECOPD. However, their use varied widely across provinces. Drug insurance formulary criteria and enforcement may be a key to facilitating better antibiotic stewardship and limiting potentially inappropriate first-line use of fluoroquinolones.
dc.identifier.citationBMC Infectious Diseases. 2021 Aug 03;21(1):733
dc.identifier.doihttps://doi.org/10.1186/s12879-021-06467-z
dc.identifier.urihttp://hdl.handle.net/1880/113716
dc.language.rfc3066en
dc.rights.holderThe Author(s)
dc.titleRegional variation in the potentially inappropriate first-line use of fluoroquinolones in Canada as a key to antibiotic stewardship? A drug utilization review study
dc.typeJournal Article
Files
Original bundle
Now showing 1 - 1 of 1
Thumbnail Image
Name:
12879_2021_Article_6467.pdf
Size:
918.45 KB
Format:
Adobe Portable Document Format
Description:
Download
License bundle
Now showing 1 - 1 of 1
Thumbnail Image
Name:
license.txt
Size:
0 B
Format:
Item-specific license agreed upon to submission
Description:
Download
Collections
Open Access Publications